This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Park, J. M. Articles by Berzofsky, J. A. Search for Related Content PubMed PubMed Citation Articles by Park, J. M. Articles by Berzofsky, J. A.

Therapy of Advanced Established Murine Breast Cancer with a Recombinant Adenoviral ErbB-2/neu Vaccine

¹ Vaccine Branch and ² Metabolism Branch, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, Maryland; and ³ Molecular Biotechnology Center, Clinical and Biological Sciences, University of Turin, Turin, Italy

Requests for reprints: Masaki Terabe, National Cancer Institute, NIH, Building 10, Room 6B-12, 9000 Rockville Pike, Bethesda, MD 20892-1578. Phone: 301-435-8349; Fax: 301-402-0549; E-mail: terabe{at}mail.nih.gov.

Key Words: Advanced cancer • Breast cancer • Vaccine therapy

ErbB-2 (HER-2/neu) is a transforming oncogene expressed by a substantial fraction of breast cancers, and monoclonal antibody therapy directed toward this antigen is an established treatment modality. However, not all tumors respond, and with a monoclonal antibody directed to a single epitope, there is always the risk of tumor escape. Furthermore, passive antibody therapy requires continual treatment. Whereas cancer vaccines have prevented the growth of tumors, it has been far more difficult to treat large established tumors. Here, we show that vaccination with a recombinant adenovirus expressing a truncated ErbB-2 antigen can cure large established subcutaneous ErbB-2–expressing breast cancers in mice, and can also cure extensive established lung metastatic disease. We also show that the mechanism of protection involves antibody-mediated blockade of ErbB-2 function, independent of Fc receptors. We conclude that a vaccine inducing antibodies to a functional oncogenic receptor could have tremendous therapeutic potential against cancers overexpressing such molecules. [Cancer Res 2008;68(6):1979–87]

This article has been cited by other articles:

				J. C. Steel, C. A. Ramlogan, P. Yu, Y. Sakai, G. Forni, T. A. Waldmann, and J. C. Morris Interleukin-15 and Its Receptor Augment Dendritic Cell Vaccination against the neu Oncogene through the Induction of Antibodies Partially Independent of CD4 Help Cancer Res., February 1, 2010; 70(3): 1072 - 1081. [Abstract] [Full Text] [PDF]